TY  - JOUR
AU  - Chalmers, James D.
AU  - Metersky, Mark L.
AU  - Puente Maestu, Luis
PY  - 2025
DO  - 10.1056/NEJMoa2411664
SN  - 0028-4793
UR  - https://hdl.handle.net/20.500.14352/129982
T2  - N Engl J Med.
AB  - BACKGROUND: In bronchiectasis, neutrophilic inflammation is associated with an increased risk of exacerbations and disease progression. Brensocatib, an oral, reversible inhibitor of dipeptidyl peptidase 1 (DPP-1), targets neutrophil serine proteases,...
LA  - eng
M2  - 1569
PB  - Massachusetts Medical Society
KW  - Bronchiectasis
KW  - DPP-1 Inhibitor Brensocatib
TI  - Phase3 Trial of the DPP-1 Inhibitor Brensocatib in Bronchiectasis
TY  - journal article
VL  - 392
ER  -